Gyre Therapeutics (GYRE) Investor presentation summary

Company overview and merger rationale

• Combined entity leverages cost-efficient China operations for accelerated discovery, validation, and development of next-generation therapeutics based on degraders and DACs.

• Post-merger, the company will have headquarters in San Diego with subsidiaries in Beijing and Shanghai, and a leadership team with extensive international experience.

• The merger creates a robust pipeline with 10 announced therapeutic programs, including marketed, pre-NDA, Phase 1, Phase 2, and IND-enabling assets.

• The company has been EBITDA positive since 2017, with revenue growing at a 32% CAGR.

Therapeutic pipeline and technology platforms

• Broad portfolio spans inflammation, pain, fibrosis, and cancer, with assets from discovery to commercialization.

• Strong focus on targeted protein degraders and DACs, expanding druggable disease space beyond traditional small molecules.

• DACs combine advantages of ADCs and TPDs, offering high potency, improved pharmacokinetics, and enhanced safety.

• Key programs include F351 for liver fibrosis, CG001419 for pain and cancer, and CG009301 for AML and MYC+ cancers.

Clinical and preclinical highlights

• F351 met primary and secondary endpoints in Phase 3 for CHB-associated liver fibrosis, with NDA filing in China expected 1H 2026.

• CG001419 completed Phase 1 for acute pain, showing safety and dose-proportional exposure; Phase 2 bunionectomy study planned.

• CG001419 is also in Phase 1 for pan-TRK cancers, with no observed DLTs or severe adverse events in initial patients.

• CG009301, a GSPT1 degrader, is in Phase 1 for hematologic malignancies, with dose escalation ongoing.

• TYK2/JAK1 dual degrader CG620953 demonstrated superior efficacy in preclinical lupus and RA models.